SAMHD1 and acute myeloid leukemia: Toward this end, we analyzed two independent and clinically different cohorts of de novo AML to assess whether SAMHD1 protein expression in blasts at the time of diagnosis correlates with clinical endpoints, including complete remission (CR), EFS and OS, as well as the type of ara-C treatment (low-dose vs. high-dose).